Oral Semaglutide: A Promising, Safe, and Effective Option for Women with Type 2 Diabetes

A growing body of research now supports oral semaglutide as an effective and safe treatment for women with type 2 diabetes (T2D). Recent real-world and clinical trial data, published in 2025, demonstrate that this once-daily oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) significantly improves blood sugar control while promoting meaningful weight loss and showing a favorable safety profile. These findings, emerging from large patient cohorts and diverse populations, mark an important step in addressing the sex-specific needs and underrepresentation of women in diabetes research.

Key Findings and Evidence

Oral semaglutide, the first GLP-1 RA available as a tablet, has been shown to reduce HbA1c (a key marker of long-term blood glucose control) by approximately 0.7% to 1.8% over 6 to 12 months in women with T2D, while also facilitating weight loss ranging from 4.6% to 7% of body weight in real-world settings. These effects are comparable to or better than previous injectable formulations with the added advantage of oral administration, which may improve adherence.

In a major observational study including over 1,000 patients, nearly one-third of women treated with oral semaglutide experienced weight reduction exceeding 10%, alongside clinically significant HbA1c improvement. Another Indian cohort study found similar glycemic and weight benefits, with reductions in fasting plasma glucose from approximately 156 mg/dL to 104 mg/dL and HbA1c decreasing from 8.6% to 7.0% after treatment, with minimal hypoglycemia reported.

The drug’s cardiovascular safety has also been corroborated by large randomized controlled trials. Oral semaglutide reduced the risk of major adverse cardiovascular events by 14% in patients with type 2 diabetes at high cardiovascular risk, a vital consideration given the increased heart disease risk in women with T2D.

Expert Perspectives

Dr. Darren K. McGuire, Professor of Medicine at UT Southwestern Medical Center, emphasized the dual importance of glycemic control and cardiovascular risk reduction, noting oral semaglutide’s potential as a “promising option” for comprehensive diabetes management. Endocrinologists highlight the convenience of oral delivery as a game-changer, addressing barriers associated with injectables that can restrict patient acceptance and compliance.

Real-world data analyst Dr. Reyes-Garcia pointed out that women with T2D often face higher cardiovascular risks yet are underrepresented in clinical trials. She affirmed that “oral semaglutide is both effective and safe in women, helping to close this sex gap”.

Background and Context

Type 2 diabetes affects men and women differently, with women generally showing higher risks for cardiovascular complications and variable drug responses. GLP-1 receptor agonists like semaglutide work by stimulating insulin secretion, reducing glucagon levels, slowing gastric emptying, and promoting satiety, which together improve glycemic control and reduce weight.

Until recently, GLP-1 RAs were only available as injections, limiting some patients’ treatment options. Oral semaglutide, formulated with an absorption enhancer (SNAC), allows daily pill intake, facilitating broader access and integrating easily into patients’ routines.

Public Health Implications

Effective diabetes control reduces risks of complications such as kidney disease, nerve damage, vision loss, and cardiovascular disease. Women, in particular, stand to benefit as they traditionally face inequities in treatment access and research representation. The availability of a safe, effective oral treatment may improve adherence rates and outcomes, potentially reducing the burden of diabetes-related morbidity.

Healthcare professionals should consider oral semaglutide as a valuable option for women who struggle with injectable therapies or require intensified glycemic management alongside cardiovascular risk reduction.

Limitations and Considerations

Some limitations exist: the degree of weight loss and HbA1c improvement may plateau after 6 to 9 months before modestly increasing again, indicating the need for ongoing evaluation and possible dose adjustments. Additionally, while adverse effects are generally mild—primarily gastrointestinal—they can lead to treatment discontinuation in some patients.

Women with chronic kidney disease and older age may see varied responses, and more research is necessary to confirm the long-term impact and optimal dosing strategies specifically for diverse female populations.

Practical Guidance for Readers

Women with type 2 diabetes should discuss with their healthcare providers whether oral semaglutide is appropriate for their individual health profile. This medication is taken once daily with water on an empty stomach, requiring adherence to timing for maximum absorption. As with all diabetes treatments, lifestyle modifications including diet and exercise remain essential components of comprehensive care.

Patients should report side effects and undergo regular monitoring of blood sugar and kidney function. Importantly, oral semaglutide should be part of an individualized treatment plan supervised by qualified professionals.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References: